Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) Clinical Trials

Find Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) Clinical Trials Near You

Modeling of Amyotrophic Lateral Sclerosis Using Patient Fibroblasts to Study Different Form of the Disease.

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Amyotrophic Lateral Sclerosis (ALS) is the most common motor neuron disease in adults. This longitudinal study involves three cohorts of participants: patients with sporadic or hereditary ALS, asymptomatic individuals carrying pathogenic mutations responsible for ALS, and control subjects. In this study, a skin biopsy and blood sampling will be performed at the initial visit (M0), then at M12 (+/- 2 months) for patients, and at M36 (+/- 12 months) for asymptomatic carriers of pathogenic mutations. The aim of this research is to model ALS pathology using fibroblasts derived from the patients' skin biopsies.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• adults, both sexes

• with written consent to participate in the study

• affiliated to a social security scheme

⁃ ALS patients :

• patients with ALS according to the revised El Escorial criteria :

• with a hereditary form of ALS, defined by the presence of a family history of ALS or by the demonstration of a pathogenic mutation in the patient or

• with a juvenile form of the disease, defined by onset of symptoms at less than 30 years of age or

• with a sporadic form of ALS

⁃ Asymptomatic mutation carriers :

⁃ \- Asymptomatic individuals who carry a mutation causing ALS but have not developed symptoms.

⁃ Healthy subjects:

• control individuals, taking into account male/female and close age matching

Locations
Other Locations
France
CIC Neurosciences
RECRUITING
Paris
Contact Information
Primary
Maria del Mar Amador, MD
mariadelmar.amador@aphp.fr
33142162472
Time Frame
Start Date: 2025-08-28
Estimated Completion Date: 2034-09
Participants
Target number of participants: 110
Treatments
Experimental: participants (SLA, healthy controls and asymptomatics)
Patients fulfilling the El Escorial criteria definite ALS or asymptomatics or Healthy controls
Sponsors
Leads: Assistance Publique - Hôpitaux de Paris

This content was sourced from clinicaltrials.gov